Sarepta Therapeutics, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2026 am IST			After hours 05:30:00 am
15.31 ^USD	+2.07%		14.82	-3.17%

08/06	Sarepta Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 10:40 AM
04/06	Sarepta Therapeutics, Inc. - Shareholder/Analyst Call

Published on 05/07/2026 at 05:36 am IST - Modified on 05/07/2026 at 09:05 am IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good afternoon, and welcome to Sarepta's First Quarter 2026 Earnings Results Call. As a reminder, today's program is being recorded.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

08/06	Sarepta Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 10:40 AM
04/06	Sarepta Therapeutics, Inc. - Shareholder/Analyst Call
04/06	Acting US FDA chief meets with rare disease groups to mend fences	RE
01/06	Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion	RE
29/05	Replimune gets third chance at US approval for skin cancer drug	RE
15/05	Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says	MT
14/05	Regenxbio shares sink as safety concerns overshadow muscle disorder therapy trial win	RE
12/05	Trump says US FDA Commissioner Makary is out	RE
08/05	Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says	MT
07/05	Sarepta Therapeutics, Inc., Q1 2026 Earnings Call, May 06, 2026
07/05	Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Reports Q1 Revenue $730.8M	MT
07/05	Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Posts Q1 Adjusted EPS $3.16 per Share	MT
07/05	Sarepta Therapeutics, Inc. Reiterates Revenue Guidance for the Year 2026	CI
07/05	Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
17/04	Sarepta Therapeutics Seen Benefiting From New Elevidys Study, Better US Uptake in Second Half of 2026	MT